# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $17...
Jefferies analyst Kelly Shi maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $174 to $196.
Goldman Sachs analyst Paul Choi maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $170 to ...
FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous...
KEY: 24% | Scotiabank Acquires 14.9% Stake in KeyCorp With $2.8B Strategic Investment ASND: 11% | Ascendia Pharma shares are tr...